Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Inhibitory receptors on lymphocytes: insights from infections.

Odorizzi PM, Wherry EJ.

J Immunol. 2012 Apr 1;188(7):2957-65. doi: 10.4049/jimmunol.1100038. Review.

2.

[The role of co-inhibitory signals driven by CTLA-4 in immune system].

Olive D, le Thi S, Xerri L, Hirsch I, Nunès JA.

Med Sci (Paris). 2011 Oct;27(10):842-9. doi: 10.1051/medsci/20112710012. Epub 2011 Oct 21. French.

3.

Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Attanasio J, Wherry EJ.

Immunity. 2016 May 17;44(5):1052-68. doi: 10.1016/j.immuni.2016.04.022. Review.

4.

Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese.

Ge J, Zhu L, Zhou J, Li G, Li Y, Li S, Wu Z, Rong J, Yuan H, Liu Y, Chi Q, Piao D, Zhao Y, Cui B.

J Cancer Res Clin Oncol. 2015 Sep;141(9):1533-44. doi: 10.1007/s00432-015-1915-4. Epub 2015 Jan 22.

PMID:
25604582
5.

Co-inhibitory pathways and their importance in immune regulation.

Murakami N, Riella LV.

Transplantation. 2014 Jul 15;98(1):3-14. doi: 10.1097/TP.0000000000000169. Review.

PMID:
24978034
6.

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle.

Manieri NA, Chiang EY, Grogan JL.

Trends Immunol. 2017 Jan;38(1):20-28. doi: 10.1016/j.it.2016.10.002. Epub 2016 Oct 25. Review.

PMID:
27793572
7.

[T-cell costimulation. Basic mechanisms and new aspects].

Hutloff A.

Z Rheumatol. 2011 Sep;70(7):588-91. doi: 10.1007/s00393-011-0862-y. Review. German.

PMID:
21858484
8.

Inhibitory phenotype of HBV-specific CD4+ T-cells is characterized by high PD-1 expression but absent coregulation of multiple inhibitory molecules.

Raziorrouh B, Heeg M, Kurktschiev P, Schraut W, Zachoval R, Wendtner C, Wächtler M, Spannagl M, Denk G, Ulsenheimer A, Bengsch B, Pircher H, Diepolder HM, Grüner NH, Jung MC.

PLoS One. 2014 Aug 21;9(8):e105703. doi: 10.1371/journal.pone.0105703. eCollection 2014.

9.

Basics of PD-1 in self-tolerance, infection, and cancer immunity.

Chikuma S.

Int J Clin Oncol. 2016 Jun;21(3):448-55. doi: 10.1007/s10147-016-0958-0. Epub 2016 Feb 10. Review.

PMID:
26864303
10.

Clinical blockade of PD1 and LAG3--potential mechanisms of action.

Nguyen LT, Ohashi PS.

Nat Rev Immunol. 2015 Jan;15(1):45-56. doi: 10.1038/nri3790. Review.

PMID:
25534622
11.

KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults.

Boer MC, van Meijgaarden KE, Goletti D, Vanini V, Prins C, Ottenhoff TH, Joosten SA.

Tuberculosis (Edinb). 2016 Mar;97:163-71. doi: 10.1016/j.tube.2015.11.008. Epub 2015 Dec 8.

PMID:
26750180
12.

Immunotherapies: the blockade of inhibitory signals.

Wu YL, Liang J, Zhang W, Tanaka Y, Sugiyama H.

Int J Biol Sci. 2012;8(10):1420-30. doi: 10.7150/ijbs.5273. Epub 2012 Nov 17. Review.

13.

Age-dependent changes in the expression of regulatory cell surface ligands in activated human T-cells.

Canaday DH, Parker KE, Aung H, Chen HE, Nunez-Medina D, Burant CJ.

BMC Immunol. 2013 Oct 1;14:45. doi: 10.1186/1471-2172-14-45.

14.

[Inhibitory receptors of lymphocytes and their role in antitumor immunity].

Zakeeva IR, Berezhnoĭ AE, Gnuchev NV, Georgiev GP, Lapin SS.

Vopr Onkol. 2007;53(2):140-9. Review. Russian. No abstract available.

PMID:
17663166
15.

The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses.

Frebel H, Oxenius A.

Trends Immunol. 2013 May;34(5):193-9. doi: 10.1016/j.it.2012.12.002. Epub 2013 Jan 16. Review.

PMID:
23333205
16.

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.

Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM.

Nat Immunol. 2003 Jul;4(7):670-9. Epub 2003 Jun 8.

PMID:
12796776
17.

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Fife BT, Bluestone JA.

Immunol Rev. 2008 Aug;224:166-82. doi: 10.1111/j.1600-065X.2008.00662.x. Review.

PMID:
18759926
18.

The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses.

Crawford A, Wherry EJ.

Curr Opin Immunol. 2009 Apr;21(2):179-86. doi: 10.1016/j.coi.2009.01.010. Epub 2009 Mar 4. Review.

19.

T cells Exhibit Reduced Signal Transducer and Activator of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After Kidney Transplantation.

Bouvy AP, Klepper M, Kho MM, Ijzermans JN, Betjes MG, Weimar W, Baan CC.

Transplantation. 2015 Sep;99(9):1995-2003. doi: 10.1097/TP.0000000000000674.

PMID:
25769075
20.

CD4(+) T-cell inhibitory ligands: a tool for characterizing dysfunctional CD4(+) T cells during chronic infection.

Dow C, Henderson R, Sette A, Mothé BR.

Immunology. 2013 Sep;140(1):61-9. doi: 10.1111/imm.12109. Erratum in: Immunology. 2013 Nov;140(3):390.

Supplemental Content

Support Center